Statements (41)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
phenothiazine derivative |
| gptkbp:administeredBy |
palliative care
end-of-life care |
| gptkbp:ATCCode |
N05AA02
|
| gptkbp:availableOn |
gptkb:tablet
injectable solution |
| gptkbp:brand |
gptkb:Nozinan
|
| gptkbp:CASNumber |
60-04-4
|
| gptkbp:category |
analgesic
antipsychotic medication antiemetic |
| gptkbp:chemicalFormula |
C18H24N2OS
|
| gptkbp:contraindication |
bone marrow depression
severe CNS depression hypersensitivity to phenothiazines |
| gptkbp:discoveredBy |
gptkb:Rhodia
|
| gptkbp:discoveredIn |
1950s
|
| gptkbp:eliminationHalfLife |
15-30 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
methotrimeprazine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antihistamine
dopamine receptor antagonist anticholinergic alpha-adrenergic blocker |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
|
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
hypotension
sedation extrapyramidal symptoms anticholinergic effects |
| gptkbp:synonym |
levomepromazine
|
| gptkbp:usedFor |
nausea
schizophrenia pain management agitation |
| gptkbp:bfsParent |
gptkb:Levomepromazine
|
| gptkbp:bfsLayer |
7
|